In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. Is there a buying ...

Get a high-probability setup with clear entry and exit points right here. Vertex Pharmaceuticals Inc VRTX announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

Vertex Pharmaceuticals is up 13.5% during the same time and is heading into earnings with an average analyst price target of ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...